ClinicaliQ Trial Snapshot
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07258511.
- What is being tested: JNJ-79635322 is being directly compared with a BCMA×CD3 bispecific antibody—both novel immunotherapies designed to engage T cells against BCMA-expressing myeloma cells—to evaluate comparative efficacy and safety in relapsed or refractory disease.
- Patient eligibility overview: The trial includes patients with relapsed or refractory multiple myeloma; these represent treatment-resistant cases where standard therapies have failed, typically after prior lines of therapy including proteasome inhibitors and immunomodulatory drugs.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Eligibility Snapshot
- Inclusion: * Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: 1. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria 2. Measurable disease at screening as assessed by central laboratory * Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody * Documented evidence of progressive disease (PD) or failure to achieve a response (that is partial response [PR] or better) to the last line of therapy based on investigator's determination of response by IMWG criteria * Have discontinued concurrent use of any other anticancer treatment (including nonpalliative radiotherapy) or investigational agent * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration Exclusion: * Active hepatitis of infectious origin * Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM * Suspected or known allergies, hypersensitivity, or intolerance to the excipients of JNJ-79635322 and Teclistamab * Major surgery , (example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.